|

MR Microstructural Imaging for Prostate Cancer Diagnosis

RECRUITINGSponsored by First Affiliated Hospital of Zhejiang University
Actively Recruiting
SponsorFirst Affiliated Hospital of Zhejiang University
Started2020-09-01
Est. completion2028-12-31
Eligibility
SexMALE
Healthy vol.Accepted

Summary

The goal of this multi-center clinical study is to evaluate whether time-dependent diffusion MRI (TDDMRI) can provide reliable microstructural imaging markers for the diagnosis of prostate cancer. The main questions this study aims to answer are: * Do TDDMRI-derived microstructural parameters (such as cell size and density) improve diagnostic accuracy for prostate cancer compared with conventional MRI? * How well do the microstructural parameters correlate with whole-slide pathology findings? * Can the investigators determine diagnostic models combining multiple features for presurgical diagnosis across multiple centers? Participants with suspected prostate cancer will undergo 3T MRI including TDDMRI. Microstructural parameters will be quantified and compared with standard multiparametric MRI. All participants will also receive prostate biopsy or prostatectomy, and imaging findings will be validated against histopathology. This study will: * Collect TDDMRI and conventional MRI data from six hospitals. * Derive and validate imaging markers of prostate cancer based on microstructural parameters. * Compare diagnostic performance across centers and against pathology as the reference standard.

Eligibility

Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* Clinical suspicion of prostate cancer (elevated PSA, abnormal digital rectal examination, or other clinical indication).
* Undergoing prostate MRI including TDDMRI as part of diagnostic evaluation. Able and willing to provide written informed consent.

Exclusion Criteria:

* Contraindications to MRI (e.g., pacemaker, ferromagnetic implants, severe claustrophobia).
* Prior treatment for prostate cancer (surgery, radiation, hormonal therapy, chemotherapy).
* Severe comorbid conditions precluding MRI or biopsy.
* Inability to provide informed consent.
* Poor image quality due to motion or technical artifacts (assessed at imaging QC).

Conditions3

CancerDiffusion MRIProstate Cancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.